Botanix Pharmaceuticals Limited BXPHF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 254.21% | 253.62% | 4,303.82% | 4,168.38% | 210.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 254.21% | 253.62% | 4,303.82% | 4,168.38% | 210.96% |
| Cost of Revenue | 262.69% | 262.08% | 396.67% | 381.53% | -6.83% |
| Gross Profit | 246.59% | 246.01% | 1,378.03% | 1,339.19% | 381.87% |
| SG&A Expenses | -8.49% | -8.64% | 44.19% | 39.78% | 589.82% |
| Depreciation & Amortization | 9.32% | 9.13% | 6.86% | 3.60% | 1,639.34% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.20% | 4.03% | 56.07% | 51.30% | 439.35% |
| Operating Income | 22.35% | 22.48% | -5.91% | -2.67% | -484.97% |
| Income Before Tax | 26.98% | 27.10% | -8.25% | -4.94% | -542.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.98% | 27.10% | -8.25% | -4.94% | -542.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.98% | 27.10% | -8.25% | -4.94% | -542.17% |
| EBIT | 22.35% | 22.48% | -5.91% | -2.67% | -484.97% |
| EBITDA | 23.08% | 23.21% | -5.88% | -2.64% | -476.19% |
| EPS Basic | 42.11% | 41.94% | 0.00% | 3.51% | -427.78% |
| Normalized Basic EPS | 42.37% | 41.38% | 0.00% | 2.78% | -436.36% |
| EPS Diluted | 42.11% | 41.94% | 0.00% | 3.51% | -427.78% |
| Normalized Diluted EPS | 42.37% | 41.38% | 0.00% | 2.78% | -436.36% |
| Average Basic Shares Outstanding | 26.30% | 26.30% | 8.11% | 8.11% | 19.73% |
| Average Diluted Shares Outstanding | 26.30% | 26.30% | 8.11% | 8.11% | 19.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |